Compare REED & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REED | ACON |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.4M |
| IPO Year | 2009 | 2022 |
| Metric | REED | ACON |
|---|---|---|
| Price | $1.05 | $2.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 6.4K | ★ 56.5K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,065,000.00 | $75,730.00 |
| Revenue This Year | $18.74 | $87.22 |
| Revenue Next Year | $18.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.62 |
| 52 Week Low | $0.73 | $1.95 |
| 52 Week High | $5.97 | $12.03 |
| Indicator | REED | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 54.00 |
| Support Level | $0.76 | $2.62 |
| Resistance Level | $1.42 | $3.54 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 69.59 | 68.50 |
Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.